Skip to content
Biodatica
Start free

Tanabe Pharma Corporation

Nagoya, Aichi-ken

OncologyPhase III
Compare Sign in to watch

What changed

Phase II trial registered: A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

5w agoTrial registeredJun 9, 2026Source filing (opens the source filing in a new tab)

Momentum

93no change

Momentum 93 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

215 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1/PHASE2 registered

    Jan 30, 2023

    Diffuse Large B-Cell Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Tanabe Pharma Corporation · A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

    ClinicalTrials.gov · NCT05658562 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Oct 26, 2022

    ALS · COMPLETED · sponsor: Tanabe Pharma Corporation · Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS

    ClinicalTrials.gov · NCT05568615 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    Mar 5, 2018

    Anemia; Hemodialysis Dependent Chronic Kidney Disease · COMPLETED · sponsor: Tanabe Pharma Corporation · Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

    ClinicalTrials.gov · NCT03461146 (opens the source filing in a new tab)

  4. Trial

    PHASE3 registered

    Feb 14, 2018

    Anemia; Hemodialysis Dependent Chronic Kidney Disease · COMPLETED · sponsor: Tanabe Pharma Corporation · Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

    ClinicalTrials.gov · NCT03439137 (opens the source filing in a new tab)

  5. Trial

    PHASE2/PHASE3 registered

    Jun 21, 2017

    Tardive Dyskinesia · COMPLETED · sponsor: Tanabe Pharma Corporation · Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia

    ClinicalTrials.gov · NCT03176771 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources